ENTX · Entera Bio Ltd.
$3.03
-0.05 (-1.62%)
At close · Aug 28
Going-concern doubt
— cleared Aug 7, 2026
The latest filing states the doubt was alleviated.
“Following the closing of the private placement and receipt of the related net proceeds, management concluded that substantial doubt about the Company's ability to continue as a going concern no longer exists.”View the 10-Q filed Aug 7, 2026
Market Cap
$533.28M
Shares
173.14M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.03
Open$3.12
Day$3.00–3.15
52W close$1.00–3.92
Avg vol 30d3.4M
Short int957K · 0.6% float · 1.9d
Short vol53%
Last earningsApr 20, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 7
Up next
Next earnings call
May 11, 2028
Est · unconfirmed
· in 89 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+74%
above
Price vs 50-day avg
+26%
above
RSI (14)
55
neutral
MACD trend
Negative
52-week position
70%
mid-range
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+128%
trailing
YTD return
+56%
this year
Relative strength
+114%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.55% of float · ▼ -16.8% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
27 holders — near 3-yr high, broad support
Squeeze score
40
elevated · 0–100
Fundamentals
Revenue growth
−77%
Y/Y
Gross margin
0%
contracting
EPS growth
0%
Y/Y
Free cash flow
$-7.5M
Quant / Vol
risk profile
Volatility
129%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
9.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+74%
Bullish
Price vs 50-day avg
+26%
Bullish
RSI (14)
55
Neutral
MACD trend
Negative
Bearish
52-week position
70%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.55% of float · ▼ -16.8% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
27 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $3 · 70%
Range high $4
vs 200-day avg +74%
vs 50-day avg +26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENTX
this stock
Entera Bio Ltd.
|
$533.28M | +56.2% | -76.8% | — | 0.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +2.9% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
27
- % held
- 6.2%
- Net QoQ
- +2.9M sh
- Top holder
- Knoll Capital Management,…
Held
Float
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENTX | -6.2% | +1.3% | +127.8% | +1.3% | +56.2% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -6.7% | -1.7% | +114.4% | -1.7% | +43.4% |
Key facts
CIK
1638097
CUSIP
M40527109
13F (30d)
31 filings
30 filers
Visit website
Investor relations